Eli Lilly (LLY) Offering Possible 25.63% Return Over the Next 7 Calendar Days

Eli Lilly’s most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $116.00 short put and a strike $111.00 long put offers a potential 25.63% return on risk over the next 7 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $116.00 by expiration. The full premium credit of $1.02 would be kept by the premium seller. The risk of $3.98 would be incurred if the stock dropped below the $111.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.

The RSI indicator is at 71.53 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Eli Lilly

[$$] Big Pharma’s Cancer Race
Thu, 10 Jan 2019 00:32:34 +0000
Eli Lilly’s bid for Loxo Oncology, which follows a flurry of biotech deals, shows how the pharmaceutical landscape is fast-evolving as U.S. drug companies compete to become leaders in oncology. Indianapolis-based Eli Lilly on Monday announced plans to purchase the Stamford, Conn., start-up Loxo for $8 billion with the goal of expanding its oncology portfolio. Loxo has pioneered an experimental therapy targeting single-gene abnormalities that can cause tumors throughout the body.

Wed, 09 Jan 2019 19:32:00 +0000
Jamie Dimon held a private dinner with executives from pharmaceutical companies including Eli Lilly, Pfizer and Johnson & Johnson. The attendees pressed him for information on Amazon’s goals. J.P. Morgan Chase CEO Jamie Dimon hosted a private dinner for pharmaceutical executives on Sunday night, ahead of the bank’s health-care conference in San Francisco.

MERGER ALERT – BDMS, LOXO and MB: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies
Wed, 09 Jan 2019 16:56:39 +0000
NEW YORK, Jan. 09, 2019 — The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.

The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo
Wed, 09 Jan 2019 13:51:01 +0000
The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo

Novartis’ Crizanlizumab Gets Breakthrough Therapy Status
Wed, 09 Jan 2019 13:31:01 +0000
Novartis’s (NVS) crizanlizumab gets Breakthrough Therapy designation by the FDA for the prevention of VOCs in patients of all genotypes with SCD.

Be Sociable, Share!

Related Posts